| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $88,102,510 | 41 | 100 |
| Norden Gregory | director | 0 | $0 | 1 | $161,385 | $-161,385 |
| Urist Marshall | EVP, Research & Investments | 0 | $0 | 16 | $12.54M | $-12.54M |
| Lloyd George W. | EVP, Investments & CLO | 0 | $0 | 4 | $13.81M | $-13.81M |
| Hite Christopher | EVP & Chairman, Partnering | 0 | $0 | 3 | $20.01M | $-20.01M |
| Coyne Terrance P. | EVP & CFO | 0 | $0 | 17 | $41.58M | $-41.58M |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Over the last 12 months, insiders at Royalty Pharma plc have bought $0 and sold $88.1M worth of Royalty Pharma plc stock.
On average, over the past 5 years, insiders at Royalty Pharma plc have bought $10.26M and sold $89.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 130,000 shares for transaction amount of $3.84M was made by Legorreta Pablo G. (CEO, Chairman of the Board) on 2023‑06‑28.
| 2026-10-05 | Sale | Urist Marshall | EVP, Research & Investments | 4,126 0.0009% | $57.10 | $235,595 | +9.69% | |
| 2026-09-28 | Sale | Urist Marshall | EVP, Research & Investments | 4,126 0.0009% | $57.88 | $238,813 | +2.70% | |
| 2026-09-22 | Sale | Hite Christopher | EVP & Chairman, Partnering | 100,000 0.0226% | $58.53 | $5.85M | +0.27% | |
| 2026-08-18 | Sale | Hite Christopher | EVP & Chairman, Partnering | 100,000 0.0227% | $59.97 | $6M | +1.23% | |
| 2026-08-13 | Sale | Coyne Terrance P. | EVP & CFO | 11,002 0.0025% | $58.68 | $645,551 | +2.35% | |
| 2026-07-01 | Sale | Urist Marshall | EVP, Research & Investments | 9,099 0.0021% | $55.88 | $508,454 | +5.33% | |
| 2026-06-24 | Sale | Urist Marshall | EVP, Research & Investments | 9,098 0.0021% | $55.18 | $502,067 | +8.15% | |
| 2026-06-23 | Sale | Hite Christopher | EVP & Chairman, Partnering | 150,000 0.0343% | $54.40 | $8.16M | +6.06% | |
| 2026-05-26 | Sale | Coyne Terrance P. | EVP & CFO | 64,399 0.015% | $53.98 | $3.48M | +8.51% | |
| 2026-05-20 | Sale | Urist Marshall | EVP, Research & Investments | 13,684 0.0032% | $52.75 | $721,838 | +10.12% | |
| 2026-05-14 | Sale | Norden Gregory | director | 3,045 0.0007% | $53.00 | $161,385 | +9.78% | |
| 2026-05-14 | Sale | Urist Marshall | EVP, Research & Investments | 13,684 0.0032% | $53.06 | $726,137 | +9.78% | |
| 2026-04-28 | Sale | Coyne Terrance P. | EVP & CFO | 34,791 0.0082% | $49.78 | $1.73M | +17.30% | |
| 2026-04-01 | Sale | Coyne Terrance P. | EVP & CFO | 34,791 0.0081% | $48.33 | $1.68M | +18.40% | |
| 2026-03-23 | Sale | Coyne Terrance P. | EVP & CFO | 34,791 0.0081% | $45.53 | $1.58M | +25.43% | |
| 2026-03-02 | Sale | Coyne Terrance P. | EVP & CFO | 34,791 0.0082% | $46.78 | $1.63M | +19.39% | |
| 2026-02-23 | Sale | Coyne Terrance P. | EVP & CFO | 34,791 0.0081% | $45.32 | $1.58M | +24.01% | |
| 2026-02-04 | Sale | Coyne Terrance P. | EVP & CFO | 20,163 0.0046% | $43.29 | $872,913 | +28.24% | |
| 2026-02-03 | Sale | Coyne Terrance P. | EVP & CFO | 114,954 0.0264% | $42.84 | $4.92M | +30.02% | |
| 2026-02-02 | Sale | Coyne Terrance P. | EVP & CFO | 108,424 0.0248% | $42.08 | $4.56M | +31.82% |
| Hite Christopher | EVP & Chairman, Partnering | 270401 0.0607% | $17.95M | 1 | 4 | <0.0001% |
| Coyne Terrance P. | EVP & CFO | 0 0% | $0 | 1 | 26 | <0.0001% |
| Lloyd George W. | EVP, Investments & CLO | 0 0% | $0 | 1 | 38 | <0.0001% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10 percent owner | 38714280 8.6944% | $2.57B | 1 | 2 | <0.0001% |
| Giuliani Mario Germano | director | 7795072 1.7506% | $517.59M | 1 | 10 | <0.0001% |
| Lappe Mark | 4292136 0.9639% | $285M | 10 | 0 | ||
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 2862560 0.6429% | $190.07M | 14 | 3 | |
| Efficacy Capital, Ltd. | 10 percent owner | 2552233 0.5732% | $169.47M | 36 | 20 | |
| FORD WILLIAM E | director | 1500000 0.3369% | $99.6M | 1 | 0 | <0.0001% |
| Legorreta Pablo G. | CEO, Chairman of the Board | 600000 0.1347% | $39.84M | 7 | 0 | <0.0001% |
| Fernandez Henry A | director | 58200 0.0131% | $3.86M | 2 | 0 | <0.0001% |
| RIGGS RORY B | director | 20099 0.0045% | $1.33M | 1 | 28 | <0.0001% |
| REED JOHN C | director | 3846 0.0009% | $255,374.40 | 1 | 0 | |
| Masterson Nola E | director | 0 0% | $0 | 6 | 1 |
| Increased Positions | 341 | +76.29% | 42M | +12.71% |
| Decreased Positions | 194 | -43.4% | 19M | -5.61% |
| New Positions | 104 | New | 6M | New |
| Sold Out Positions | 49 | Sold Out | 4M | Sold Out |
| Total Postitions | 594 | +32.89% | 357M | +7.1% |
| Morgan Stanley | $1.72M | 10.34% | 44.16M | -2M | -5.24% | 2025-09-30 |
| Fmr Llc | $1.09M | 6.55% | 27.99M | -12M | -30.65% | 2025-09-30 |
| Capital International Investors | $1.06M | 6.37% | 27.21M | +5M | +24.37% | 2025-09-30 |
| Blackrock, Inc. | $1.02M | 6.14% | 26.2M | +771,647 | +3.04% | 2025-09-30 |
| Baillie Gifford & Co | $675,095.00 | 4.07% | 17.37M | -647,953 | -3.6% | 2025-09-30 |
| Swedbank Ab | $474,102.00 | 2.86% | 12.2M | +42,800 | +0.35% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $464,984.00 | 2.8% | 11.97M | +6M | +99.43% | 2025-09-30 |
| Vanguard Group Inc | $424,994.00 | 2.56% | 10.94M | -25M | -69.94% | 2025-09-30 |
| State Street Corp | $399,199.00 | 2.41% | 10.27M | +77,815 | +0.76% | 2025-09-30 |
| Geode Capital Management, Llc | $296,013.00 | 1.78% | 7.62M | -559,091 | -6.84% | 2025-09-30 |